An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.

Trial Profile

An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 12 Sep 2017 Results (n=458) presented at the 42nd European Society for Medical Oncology Congress
    • 31 Aug 2017 According to an Eisai Inc media release, the company will present the new clinical data from this trial at European Society of Medical Oncology (ESMO) 2017.
    • 03 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top